The next TWO generics could launch ANY day. They will nearly double the generic revenues. These next few generics have larger markets and few if any competition. What if Isradipine is found to stop Parkinson's from progressing? This maybe seen before the studies end. Hong Kong undisclosed will be a triple hit!